High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
First Claim
1. A high-purity inhalable insulin material for a pulmonary pharmaceutical product to be delivered by metered dose inhaler, comprising:
- insulin particles having a particle size at the micrometer level, and having the following characteristics;
(i) the purity of the insulin particles being not less than 96% by weight on the dried basis;
(ii) the amount of zinc in the insulin particles being not more than 1% by weight, and not less than 0.3% by weight, on the dried basis;
(iii) the total amount of insulin-related impurities consisting of insulin dimer, high molecular weight proteins, and A-21 desamido insulin in the insulin particles being not more than 2% by weight on the dried basis, wherein, of the total amount of insulin-related impurities, the total amount of A-21 desamido insulin is less than or equal to 0.63%, and/or the total amount of insulin dimer is less than or equal to 0.13%, by weight on the dried basis;
(iv) the total amount of solvent-related impurities in the insulin particles, which solvent-related impurities do not include a co-solvent formulation component in the pulmonary product, being not more than 0.03% by weight on the dried basis; and
(v) the total amount of nonsolvent-related impurities other than insulin-related impurities in the insulin particles being not more than 0.3% by weight on the dried basis.
4 Assignments
0 Petitions
Accused Products
Abstract
A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 μm, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.
21 Citations
8 Claims
-
1. A high-purity inhalable insulin material for a pulmonary pharmaceutical product to be delivered by metered dose inhaler, comprising:
-
insulin particles having a particle size at the micrometer level, and having the following characteristics; (i) the purity of the insulin particles being not less than 96% by weight on the dried basis; (ii) the amount of zinc in the insulin particles being not more than 1% by weight, and not less than 0.3% by weight, on the dried basis; (iii) the total amount of insulin-related impurities consisting of insulin dimer, high molecular weight proteins, and A-21 desamido insulin in the insulin particles being not more than 2% by weight on the dried basis, wherein, of the total amount of insulin-related impurities, the total amount of A-21 desamido insulin is less than or equal to 0.63%, and/or the total amount of insulin dimer is less than or equal to 0.13%, by weight on the dried basis; (iv) the total amount of solvent-related impurities in the insulin particles, which solvent-related impurities do not include a co-solvent formulation component in the pulmonary product, being not more than 0.03% by weight on the dried basis; and (v) the total amount of nonsolvent-related impurities other than insulin-related impurities in the insulin particles being not more than 0.3% by weight on the dried basis. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. A high-purity inhalable insulin material for a pulmonary pharmaceutical product to be delivered by metered dose inhaler, consisting of:
-
unencapsulated insulin particles having a particle size at the micrometer level, and having the following characteristics; (i) the purity of the unencapsulated insulin particles being not less than 96% by weight on the dried basis; (ii) the amount of zinc in the unencapsulated insulin particles being not more than 1% by weight, and not less than 0.3% by weight, on the dried basis; (iii) the total amount of insulin-related impurities consisting of insulin dimer, high molecular weight proteins, and A-21 desamido insulin in the unencapsulated insulin particles being not more than 2% by weight on the dried basis, wherein, of the total amount of insulin-related impurities, the total amount of A-21 desamido insulin is less than or equal to 0.63%, and/or the total amount of insulin dimer is less than or equal to 0.13%, by weight on the dried basis; (iv) the total amount of solvent-related impurities in the unencapsulated insulin particles, which solvent-related impurities do not include a co-solvent formulation component in the pulmonary product, being not more than 0.03% by weight on the dried basis; and (v) the total amount of nonsolvent-related impurities other than insulin-related impurities in the unencapsulated insulin particles being not more than 0.3% by weight on the dried basis. - View Dependent Claims (8)
-
Specification